8-K current report · filed Oct 28, 2026

Axogen, Inc. (AXGN) 8-K Current Report: October 28, 2026

Item 2.02Item 7.01Item EX-99.2Item EX-99.1Item EX-99.3AXGN overview

Short answer

Axogen, Inc. (AXGN) filed an 8-K current report with the SEC on October 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.3 (Exhibit EX-99.3). Axogen announced third-quarter 2026 financial results on October 28, 2026.

Axogen, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Axogen announced third-quarter 2026 financial results on October 28, 2026
  • Full financial results and management commentary are contained in Exhibit 99.1, the accompanying earnings release

Item 7.01 · Regulation FD Disclosure

  • Q3 2026 financial results presentation posted October 28, 2026, providing investor-facing performance information
  • Updated corporate presentation posted October 28, 2026, signaling refreshed company strategy and business overview
  • Presentations available for analyst and investor discussions through Axogen’s investor-relations website

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $75.8M, up 26.2% YoY, with broad-based growth across major markets
  • Adjusted EBITDA $13.4M, up from $9.2M, while gross margin declined to 74.8% from 76.6%
  • 2026 revenue guidance raised to at least $290M, representing at least 29% growth, including $7M from BioCircuit
  • $225M net offering proceeds funded the $200M BioCircuit acquisition, creating substantial shareholder dilution
  • Cash, restricted cash and investments reached $350.1M, while debt was eliminated by September 30, 2026

Item EX-99.2 · Exhibit EX-99.2

  • Q3 revenue $75.8M, up 26.2% YoY, extending strong growth across Axogen’s nerve-care markets
  • Adjusted EBITDA $13.4M, margin 17.7% versus 15.4%, signaling operating leverage despite expanded commercial investment
  • Cash, equivalents, restricted cash and investments $350.1M with no debt obligations, supporting further sales and product-development spending
  • Full-year guidance: revenue growth at least 29% to $290M, organic growth at least 26% to $283M, gross margin at least 73%
  • Prostate program reached 220+ procedures across 15 clinical sites, with detailed outcomes scheduled for November 9, 2026

Item EX-99.3 · Exhibit EX-99.3

  • Corporate presentation outlines a $5.6B U.S. nerve-care opportunity, with minimal current penetration and more than 1.5M annual injuries in focus markets
  • 2026 guidance: revenue growth at least 29% to $290M, organic growth at least 26% to $283M, gross margin at least 73%, positive free cash flow
  • Commercial expansion targets extremities, breast, oral/maxillofacial and head-and-neck, plus prostate applications with projected 15%-20% CAGR
  • Avance coverage expanded to 87.6M additional lives since Q2 2025, supporting reimbursement-driven adoption
  • Key execution risks: clinical outcomes, regulatory approvals, surgeon adoption, reimbursement, supply chain pressures and hospital staffing challenges

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Axogen, Inc. 8-K filings

Get the next AXGN 8-K as it lands

Follow AXGN for push alerts, or ask the research agent what this filing means.